Balancing risk and benefit in venous thromboembolism trials: Concept for a bivariate endpoint trial design and analytic approach

J. M. Kittelson, A. C. Spyropoulos, J. L. Halperin, C. M. Kessler, S. Schulman, G. Steg, A. G G Turpie, N. R. Cutler, W. R. Hiatt, Neil Goldenberg

Research output: Contribution to journalArticle

Abstract

Antithrombotic trials in venous thromboembolism treatment and prevention, including those evaluating the new oral anticoagulants, have typically evaluated thromboembolism risk as an efficacy endpoint and bleeding risk as a separate safety endpoint. Findings often occur in opposition (i.e. decreased thromboembolism accompanied by increased bleeding, or vice-versa), leading to variable interpretation of the results, which may ultimately be judged as equivocal. In this paper, we offer an alternative to traditional designs based on the concept of a bivariate primary endpoint that accounts for simultaneous effects on antithrombotic efficacy and harm due to bleeding. We suggest a bivariate endpoint as a general approach to the assessment of 'net clinical benefit' in recently published trials and to the design of future trials. Lastly, we illustrate the bivariate endpoint design using two examples: a recently published superiority trial of rivaroxaban (RECORD1) and an ongoing non-inferiority trial of the duration of anticoagulant therapy in children with venous thrombosis (Kids-DOTT).

Original languageEnglish (US)
Pages (from-to)1443-1448
Number of pages6
JournalJournal of Thrombosis and Haemostasis
Volume11
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Venous Thromboembolism
Thromboembolism
Hemorrhage
Anticoagulants
Venous Thrombosis
Safety
Therapeutics

Keywords

  • Anticoagulants
  • Safety
  • Treatment efficacy
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Balancing risk and benefit in venous thromboembolism trials : Concept for a bivariate endpoint trial design and analytic approach. / Kittelson, J. M.; Spyropoulos, A. C.; Halperin, J. L.; Kessler, C. M.; Schulman, S.; Steg, G.; Turpie, A. G G; Cutler, N. R.; Hiatt, W. R.; Goldenberg, Neil.

In: Journal of Thrombosis and Haemostasis, Vol. 11, No. 8, 08.2013, p. 1443-1448.

Research output: Contribution to journalArticle

Kittelson, JM, Spyropoulos, AC, Halperin, JL, Kessler, CM, Schulman, S, Steg, G, Turpie, AGG, Cutler, NR, Hiatt, WR & Goldenberg, N 2013, 'Balancing risk and benefit in venous thromboembolism trials: Concept for a bivariate endpoint trial design and analytic approach', Journal of Thrombosis and Haemostasis, vol. 11, no. 8, pp. 1443-1448. https://doi.org/10.1111/jth.12324
Kittelson, J. M. ; Spyropoulos, A. C. ; Halperin, J. L. ; Kessler, C. M. ; Schulman, S. ; Steg, G. ; Turpie, A. G G ; Cutler, N. R. ; Hiatt, W. R. ; Goldenberg, Neil. / Balancing risk and benefit in venous thromboembolism trials : Concept for a bivariate endpoint trial design and analytic approach. In: Journal of Thrombosis and Haemostasis. 2013 ; Vol. 11, No. 8. pp. 1443-1448.
@article{cff1a3b61c7e4c17813f165c553c53eb,
title = "Balancing risk and benefit in venous thromboembolism trials: Concept for a bivariate endpoint trial design and analytic approach",
abstract = "Antithrombotic trials in venous thromboembolism treatment and prevention, including those evaluating the new oral anticoagulants, have typically evaluated thromboembolism risk as an efficacy endpoint and bleeding risk as a separate safety endpoint. Findings often occur in opposition (i.e. decreased thromboembolism accompanied by increased bleeding, or vice-versa), leading to variable interpretation of the results, which may ultimately be judged as equivocal. In this paper, we offer an alternative to traditional designs based on the concept of a bivariate primary endpoint that accounts for simultaneous effects on antithrombotic efficacy and harm due to bleeding. We suggest a bivariate endpoint as a general approach to the assessment of 'net clinical benefit' in recently published trials and to the design of future trials. Lastly, we illustrate the bivariate endpoint design using two examples: a recently published superiority trial of rivaroxaban (RECORD1) and an ongoing non-inferiority trial of the duration of anticoagulant therapy in children with venous thrombosis (Kids-DOTT).",
keywords = "Anticoagulants, Safety, Treatment efficacy, Venous thromboembolism",
author = "Kittelson, {J. M.} and Spyropoulos, {A. C.} and Halperin, {J. L.} and Kessler, {C. M.} and S. Schulman and G. Steg and Turpie, {A. G G} and Cutler, {N. R.} and Hiatt, {W. R.} and Neil Goldenberg",
year = "2013",
month = "8",
doi = "10.1111/jth.12324",
language = "English (US)",
volume = "11",
pages = "1443--1448",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Balancing risk and benefit in venous thromboembolism trials

T2 - Concept for a bivariate endpoint trial design and analytic approach

AU - Kittelson, J. M.

AU - Spyropoulos, A. C.

AU - Halperin, J. L.

AU - Kessler, C. M.

AU - Schulman, S.

AU - Steg, G.

AU - Turpie, A. G G

AU - Cutler, N. R.

AU - Hiatt, W. R.

AU - Goldenberg, Neil

PY - 2013/8

Y1 - 2013/8

N2 - Antithrombotic trials in venous thromboembolism treatment and prevention, including those evaluating the new oral anticoagulants, have typically evaluated thromboembolism risk as an efficacy endpoint and bleeding risk as a separate safety endpoint. Findings often occur in opposition (i.e. decreased thromboembolism accompanied by increased bleeding, or vice-versa), leading to variable interpretation of the results, which may ultimately be judged as equivocal. In this paper, we offer an alternative to traditional designs based on the concept of a bivariate primary endpoint that accounts for simultaneous effects on antithrombotic efficacy and harm due to bleeding. We suggest a bivariate endpoint as a general approach to the assessment of 'net clinical benefit' in recently published trials and to the design of future trials. Lastly, we illustrate the bivariate endpoint design using two examples: a recently published superiority trial of rivaroxaban (RECORD1) and an ongoing non-inferiority trial of the duration of anticoagulant therapy in children with venous thrombosis (Kids-DOTT).

AB - Antithrombotic trials in venous thromboembolism treatment and prevention, including those evaluating the new oral anticoagulants, have typically evaluated thromboembolism risk as an efficacy endpoint and bleeding risk as a separate safety endpoint. Findings often occur in opposition (i.e. decreased thromboembolism accompanied by increased bleeding, or vice-versa), leading to variable interpretation of the results, which may ultimately be judged as equivocal. In this paper, we offer an alternative to traditional designs based on the concept of a bivariate primary endpoint that accounts for simultaneous effects on antithrombotic efficacy and harm due to bleeding. We suggest a bivariate endpoint as a general approach to the assessment of 'net clinical benefit' in recently published trials and to the design of future trials. Lastly, we illustrate the bivariate endpoint design using two examples: a recently published superiority trial of rivaroxaban (RECORD1) and an ongoing non-inferiority trial of the duration of anticoagulant therapy in children with venous thrombosis (Kids-DOTT).

KW - Anticoagulants

KW - Safety

KW - Treatment efficacy

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84881582352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881582352&partnerID=8YFLogxK

U2 - 10.1111/jth.12324

DO - 10.1111/jth.12324

M3 - Article

C2 - 23773172

AN - SCOPUS:84881582352

VL - 11

SP - 1443

EP - 1448

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 8

ER -